TY  - JOUR
AU  - Hofer, T.P.
AU  - Nieto, A.*
AU  - Kaesmann, L.*
AU  - Taugner, J.*
AU  - Pelikan, C.
AU  - Katanov, D.*
AU  - Eze, C.*
AU  - Guggenberger, J.*
AU  - Belka, C.*
AU  - Nößner, E.
AU  - Manapov, F.*
C1  - 66577
C2  - 53445
TI  - Absence of CD4(+) and CD8(+) T cell expansion after primary multimodal treatment predicts early progression in inoperable stage III NSCLC.
JO  - J. Clin. Oncol.
VL  - 40
IS  - 16
PY  - 2022
SN  - 0732-183X
ER  - 

TY  - JOUR
AB  - PURPOSE: Trastuzumab is the only approved targeted drug for first-line treatment of human epidermal growth factor receptor 2-positive (HER2+) metastatic gastric cancer (mGC). However, not all patients respond and most eventually progress. The multicenter VARIANZ study aimed to investigate the background of response and resistance to trastuzumab in mGC. METHODS: Patients receiving medical treatment for mGC were prospectively recruited in 35 German sites and followed for up to 48 months. HER2 status was assessed centrally by immunohistochemistry and chromogenic in situ hybridization. In addition, HER2 gene expression was assessed using qPCR. RESULTS: Five hundred forty-eight patients were enrolled, and 77 had HER2+ mGC by central assessment (14.1%). A high deviation rate of 22.7% between central and local test results was seen. Patients who received trastuzumab for centrally confirmed HER2+ mGC (central HER2+/local HER2+) lived significantly longer as compared with patients who received trastuzumab for local HER2+ but central HER2- mGC (20.5 months, n = 60 v 10.9 months, n = 65; hazard ratio, 0.42; 95% CI, 8.2 to 14.4; P < .001). In the centrally confirmed cohort, significantly more tumor cells stained HER2+ than in the unconfirmed cohort, and the HER2 amplification ratio was significantly higher. A minimum of 40% HER2+ tumor cells and a HER2 amplification ratio of ≥ 3.0 were calculated as optimized thresholds for predicting benefit from trastuzumab. CONCLUSION: Significant discrepancies in HER2 assessment of mGC were found in tumor specimens with intermediate HER2 expression. Borderline HER2 positivity and heterogeneity of HER2 expression should be considered as resistance factors for HER2-targeting treatment of mGC. HER2 thresholds should be reconsidered. Detailed reports with quantification of HER2 expression and amplification levels may improve selection of patients for HER2-directed treatment.
AU  - Haffner, I.*
AU  - Schierle, K.*
AU  - Raimúndez, E.*
AU  - Geier, B.*
AU  - Maier, D.*
AU  - Hasenauer, J.
AU  - Luber, B.*
AU  - Walch, A.K.
AU  - Kolbe, K.*
AU  - Riera Knorrenschild, J.*
AU  - Kretzschmar, A.*
AU  - Rau, B.*
AU  - Fischer von Weikersthal, L.*
AU  - Ahlborn, M.*
AU  - Siegler, G.*
AU  - Fuxius, S.*
AU  - Decker, T.*
AU  - Wittekind, C.*
AU  - Lordick, F.*
C1  - 61686
C2  - 50393
CY  - Two Commerce Sq, 2001 Market St, Philadelphia, Pa 19103 Usa
SP  - 1468-1478
TI  - HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: Results from the prospective multicenter VARIANZ study.
JO  - J. Clin. Oncol.
VL  - 39
IS  - 13
PB  - Lippincott Williams & Wilkins
PY  - 2021
SN  - 0732-183X
ER  - 

TY  - JOUR
AB  - PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene (FLT3-ITD) have a poor prognosis, frequently relapse, and die as a result of AML. It is currently unknown whether a maintenance therapy using FLT3 inhibitors, such as the multitargeted tyrosine kinase inhibitor sorafenib, improves outcome after HCT.PATIENTS AND METHODSIn a randomized, placebo-controlled, double-blind phase II trial (SORMAIN; German Clinical Trials Register: DRKS00000591), 83 adult patients with FLT3-ITD-positive AML in complete hematologic remission after HCT were randomly assigned to receive for 24 months either the multitargeted and FLT3-kinase inhibitor sorafenib (n = 43) or placebo (n = 40 placebo). Relapse-free survival (RFS) was the primary endpoint of this trial. Relapse was defined as relapse or death, whatever occurred first.RESULTS With a median follow-up of 41.8 months, the hazard ratio (HR) for relapse or death in the sorafenib group versus placebo group was 0.39 (95% CI, 0.18 to 0.85; log-rank P = .013). The 24-month RFS probability was 53.3% (95% CI, 0.36 to 0.68) with placebo versus 85.0% (95% CI, 0.70 to 0.93) with sorafenib (HR, 0.256; 95% CI, 0.10 to 0.65; log-rank P = .002). Exploratory data show that patients with undetectable minimal residual disease (MRD) before HCT and those with detectable MRD after HCT derive the strongest benefit from sorafenib.CONCLUSION Sorafenib maintenance therapy reduces the risk of relapse and death after HCT for FLT3-ITD-positive AML.
AU  - Burchert, A.*
AU  - Bug, G.*
AU  - Fritz, L.V.*
AU  - Finke, J.*
AU  - Stelljes, M.*
AU  - Röllig, C.*
AU  - Wollmer, E.*
AU  - Wäsch, R.*
AU  - Bornhäuser, M.*
AU  - Berg, T.*
AU  - Lang, F.*
AU  - Ehninger, G.*
AU  - Serve, H.*
AU  - Zeiser, R.*
AU  - Wagner, E.M.*
AU  - Kröger, N.*
AU  - Wolschke, C.*
AU  - Schleuning, M.*
AU  - Götze, K.S.*
AU  - Schmid, C.*
AU  - Crysandt, M.*
AU  - Eßeling, E.*
AU  - Wolf, D.*
AU  - Wang, Y.*
AU  - Böhm, A.*
AU  - Thiede, C.*
AU  - Haferlach, T.*
AU  - Michel, C.*
AU  - Bethge, W.*
AU  - Wündisch, T.*
AU  - Brandts, C.*
AU  - Harnisch, S.*
AU  - Wittenberg, M.*
AU  - Hoeffkes, H.G.*
AU  - Rospleszcz, S.
AU  - Burchardt, A.*
AU  - Neubauer, A.*
AU  - Brugger, M.
AU  - Strauch, K.
AU  - Schade-Brittinger, C.*
AU  - Metzelder, S.K.*
C1  - 59685
C2  - 48933
CY  - 2318 Mill Road, Ste 800, Alexandria, Va 22314 Usa
SP  - 2993-3002
TI  - Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN).
JO  - J. Clin. Oncol.
VL  - 38
IS  - 26
PB  - Amer Soc Clinical Oncology
PY  - 2020
SN  - 0732-183X
ER  - 

TY  - JOUR
AU  - Aubele, M.
AU  - Huber, M.
AU  - Falkenberg, N.
AU  - Gross, E.*
AU  - Braselmann, H.
AU  - Walch, A.K.
AU  - Schmitt, M.*
C1  - 48936
C2  - 41544
CY  - Alexandria
TI  - uPA receptor and its interaction partners: Impact as potential therapeutic targets in triple-negative breast cancer.
JO  - J. Clin. Oncol.
VL  - 33
IS  - 28
PB  - Amer Soc Clinical Oncology
PY  - 2015
SN  - 0732-183X
ER  - 

TY  - JOUR
AB  - PURPOSE: Cytogenetically normal (CN) acute myeloid leukemia (AML) is the largest and most heterogeneous cytogenetic AML subgroup. For the practicing clinician, it is difficult to summarize the prognostic information of the growing number of clinical and molecular markers. Our purpose was to develop a widely applicable prognostic model by combining well-established pretreatment patient and disease characteristics. PATIENTS AND METHODS: Two prognostic indices for CN-AML (PINA), one regarding overall survival (OS; PINAOS) and the other regarding relapse-free survival (RFS; PINARFS), were derived from data of 572 patients with CN-AML treated within the AML Cooperative Group 99 study (www.aml-score.org. RESULTS: On the basis of age (median, 60 years; range, 17 to 85 years), performance status, WBC count, and mutation status of NPM1, CEBPA, and FLT3-internal tandem duplication, patients were classified into the following three risk groups according to PINAOS and PINARFS: 29% of all patients and 32% of 381 responding patients had low-risk disease (5-year OS, 74%; 5-year RFS, 55%); 56% of all patients and 39% of responding patients had intermediate-risk disease (5-year OS, 28%; 5-year RFS, 27%), and 15% of all patients and 29% of responding patients had high-risk disease (5-year OS, 3%; 5-year RFS, 5%), respectively. PINAOS and PINARFS stratified outcome within European LeukemiaNet genetic groups. Both indices were confirmed on independent data from Cancer and Leukemia Group B/Alliance trials. CONCLUSION: We have developed and validated, to our knowledge, the first prognostic indices specifically designed for adult patients of all ages with CN-AML that combine well-established molecular and clinical variables and that are easily applicable in routine clinical care. The integration of both clinical and molecular markers could provide a basis for individualized patient care through risk-adapted therapy of CN-AML.
AU  - Pastore, F.
AU  - Dufour, A.*
AU  - Benthaus, T.*
AU  - Metzeler, K.H.
AU  - Maharry, K.S.*
AU  - Schneider, S.*
AU  - Ksienzyk, B.*
AU  - Mellert, G.*
AU  - Zellmeier, E.*
AU  - Kakadia, P.M.*
AU  - Unterhalt, M.*
AU  - Feuring-Buske, M.*
AU  - Buske, C.*
AU  - Braess, J.*
AU  - Sauerland, M.C.*
AU  - Heinecke, A.*
AU  - Krug, U.*
AU  - Berdel, W.E.*
AU  - Buechner, T.*
AU  - Woermann, B.J.*
AU  - Hiddemann, W.
AU  - Bohlander, S.K.
AU  - Marcucci, G.*
AU  - Spiekermann, K.
AU  - Bloomfield, C.D.*
AU  - Hoster, E.*
C1  - 31033
C2  - 34113
CY  - Alexandria
SP  - 1586-1594
TI  - Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.
JO  - J. Clin. Oncol.
VL  - 32
IS  - 15
PB  - Amer Soc Clinical Oncology
PY  - 2014
SN  - 0732-183X
ER  - 

TY  - JOUR
AB  - PURPOSEReactivation of Epstein-Barr virus (EBV) after allogeneic stem-cell transplantation (SCT) can lead to severe life-threatening infections and trigger post-transplantation lymphoproliferative disease (PTLD). Since EBV-specific T cells could prevent PTLD, cellular immunotherapy has been a promising treatment option. However, generation of antigen-specific T-cell populations has been difficult within a short time frame. PATIENTS AND METHODSTo improve availability in urgent clinical conditions, we developed a rapid protocol for isolation of polyclonal EBV nuclear antigen 1 (EBNA-1) -specific T cells by using an interferon gamma (IFN-γ) capture technique.ResultsWe report on the use of adoptive transfer of EBNA-1-specific T cells in 10 pediatric and adult patients with EBV viremia and/or PTLD after SCT. No acute toxicity or graft-versus-host disease (GVHD) of more than grade 2 occurred as a result of adoptive T-cell transfer. In vivo expansion of transferred EBNA-1-specific T cells was observed in eight of 10 patients after a median of 16 days following adoptive transfer that was associated with clinical and virologic response in seven of them (70%). None of the responders had EBV-associated mortality. Within clinical responders, three patients were disease free by the day of last follow-up (2 to 36 months), three patients died of other infectious complications, and one patient died as a result of relapse of malignancy. EBV-related mortality was observed in two of 10 patients, and another patient had ongoing viremia without clinical symptoms at last follow-up. CONCLUSIONAdoptive ex vivo transfer of EBNA-1-specific T cells is a feasible and well-tolerated therapeutic option, representing a fast and efficient procedure to achieve reconstitution of antiviral T-cell immunity after SCT.
AU  - Icheva, V.*
AU  - Kayser, S.*
AU  - Wolff, D.*
AU  - Tuve, S.*
AU  - Kyzirakos, C.*
AU  - Bethge, W.*
AU  - Greil, J.*
AU  - Albert, M.H.*
AU  - Schwinger, W.*
AU  - Nathrath, M.
AU  - Schumm, M.*
AU  - Stevanovic, S.*
AU  - Handgretinger, R.*
AU  - Lang, P.*
AU  - Feuchtinger, T.*
C1  - 11082
C2  - 30501
SP  - 5-7
TI  - Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
JO  - J. Clin. Oncol.
VL  - 31
IS  - 1
PB  - Amer. Soc. Clinical Oncology
PY  - 2013
SN  - 0732-183X
ER  - 

TY  - JOUR
AB  - Purpose: Reactivation of Epstein-Barr virus (EBV) after allogeneic stem-cell transplantation (SCT) can lead to severe life-threatening infections and trigger post-transplantation lymphoproliferative disease (PTLD). Since EBV-specific T cells could prevent PTLD, cellular immunotherapy has been a promising treatment option. However, generation of antigen-specific T-cell populations has been difficult within a short time frame. Patients and Methods: To improve availability in urgent clinical conditions, we developed a rapid protocol for isolation of polyclonal EBV nuclear antigen 1 (EBNA-1) -specific T cells by using an interferon gamma (IFN-γ) capture technique. Results: We report on the use of adoptive transfer of EBNA-1-specific T cells in 10 pediatric and adult patients with EBV viremia and/or PTLD after SCT. No acute toxicity or graft-versus-host disease (GVHD) of more than grade 2 occurred as a result of adoptive T-cell transfer. In vivo expansion of transferred EBNA-1-specific T cells was observed in eight of 10 patients after a median of 16 days following adoptive transfer that was associated with clinical and virologic response in seven of them (70%). None of the responders had EBV-associated mortality. Within clinical responders, three patients were disease free by the day of last follow-up (2 to 36 months), three patients died of other infectious complications, and one patient died as a result of relapse of malignancy. EBV-related mortality was observed in two of 10 patients, and another patient had ongoing viremia without clinical symptoms at last follow-up. Conclusion: Adoptive ex vivo transfer of EBNA-1-specific T cells is a feasible and well-tolerated therapeutic option, representing a fast and efficient procedure to achieve reconstitution of antiviral T-cell immunity after SCT.
AU  - Icheva, V.*
AU  - Kayser, S.*
AU  - Wolff, D.*
AU  - Tuve, S.*
AU  - Kyzirakos, C.*
AU  - Bethge, W.A.*
AU  - Greil, J.*
AU  - Albert, M.H.*
AU  - Schwinger, W.*
AU  - Nathrath, M.
AU  - Schumm, M.A.*
AU  - Stevanovic, S.*
AU  - Handgretinger, R.*
AU  - Lang, P.*
AU  - Feuchtinger, T.*
C1  - 32909
C2  - 35292
SP  - 39-48
TI  - Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
JO  - J. Clin. Oncol.
VL  - 31
IS  - 1
PY  - 2013
SN  - 0732-183X
ER  - 

TY  - JOUR
AB  - PURPOSE: To identify a robust prognostic gene expression signature as an independent predictor of survival of patients with acute myeloid leukemia (AML) and use it to improve established risk classification. PATIENTS AND METHODS: Four independent sets totaling 499 patients with AML carrying various cytogenetic and molecular abnormalities were used as training sets. Two independent patient sets composed of 825 patients were used as validation sets. Notably, patients from different sets were treated with different protocols, and their gene expression profiles were derived using different microarray platforms. Cox regression and Kaplan-Meier methods were used for survival analyses. RESULTS: A prognostic signature composed of 24 genes was derived from a meta-analysis of Cox regression values of each gene across the four training sets. In multivariable models, a higher sum value of the 24-gene signature was an independent predictor of shorter overall (OS) and event-free survival (EFS) in both training and validation sets (P < .01). Moreover, this signature could substantially improve the European LeukemiaNet (ELN) risk classification of AML, and patients in three new risk groups classified by the integrated risk classification showed significantly (P < .001) distinct OS and EFS. CONCLUSION: Despite different treatment protocols applied to patients and use of different microarray platforms for expression profiling, a common prognostic gene signature was identified as an independent predictor of survival of patients with AML. The integrated risk classification incorporating this gene signature provides a better framework for risk stratification and outcome prediction than the ELN classification.  
AU  - Li, Z.*
AU  - Herold, T.
AU  - He, C.*
AU  - Valk, P.J.*
AU  - Chen, P.*
AU  - Jurinovic, V.*
AU  - Mansmann, U.*
AU  - Radmacher, M.D.*
AU  - Maharry, K.S.*
AU  - Sun, M.*
AU  - Yang, X.*
AU  - Huang, H.*
AU  - Jiang, X.*
AU  - Sauerland, M.C.*
AU  - Büchner, T.*
AU  - Hiddemann, W.
AU  - Elkahloun, A.*
AU  - Neilly, M.B.*
AU  - Zhang, Y.*
AU  - Larson, R.A.*
AU  - Le Beau, M.M.*
AU  - Caligiuri, M.A.*
AU  - Döhner, K.*
AU  - Bullinger, L.*
AU  - Liu, P.P.*
AU  - Delwel, R.*
AU  - Marcucci, G.*
AU  - Lowenberg, B.*
AU  - Bloomfield, C.D.*
AU  - Rowley, J.D.*
AU  - Bohlander, S.K.
AU  - Chen, J.*
C1  - 28600
C2  - 33472
SP  - 1172-1181
TI  - Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: An international collaborative study.
JO  - J. Clin. Oncol.
VL  - 31
IS  - 9
PB  - Amer. Soc. Clinical Oncology
PY  - 2013
SN  - 0732-183X
ER  - 

TY  - JOUR
AB  - Lignans--plant-derived compounds with estrogen-dependent and -independent anticarcinogenic properties--have been associated with postmenopausal breast cancer risk, but data are limited regarding their effect on survival. Dietary lignans are metabolized to enterolignans, which are subsequently absorbed and become bioavailable. We assessed the prognosis of 1,140 postmenopausal patients with breast cancer age 50 to 74 years who were diagnosed between 2002 and 2005. Vital status through the end of 2009 was ascertained via local population registries, and deaths were verified by death certificates. Information on recurrences and secondary tumors was verified by clinical records and attending physicians. Associations of postdiagnostic serum enterolactone (a biomarker for dietary lignans) with overall survival and distant disease-free survival were assessed by using Cox proportional hazards models stratified by age at diagnosis and adjusted for prognostic factors. Median enterolactone levels for deceased patients and those still alive were 17.0 and 21.4 nmol/L, respectively. During a median of 6.1 years of follow-up after diagnosis, 162 deaths were confirmed. Higher serum enterolactone levels were associated with significantly reduced hazard ratios (HRs) for death (HR per 10 nmol/L increment, 0.94; P = .04; HR for the highest quartile, 0.58; 95% CI, 0.34 to 0.99). For distant disease, HR was 0.94 per 10 nmol/L increment (P = .08) and 0.62 (95% CI, 0.35 to 1.09) for the highest quartile. The highest quartile of serum enterolactone was associated with a significantly reduced risk of death only for estrogen receptor-negative tumors (HR, 0.27; 95% CI, 0.08 to 0.87) but not for estrogen receptor-positive tumors (HR, 0.91; 95% CI, 0.45 to 1.84: P for heterogeneity = .09). Postmenopausal patients with breast cancer who have high serum enterolactone levels may have better survival.
AU  - Buck, K.*
AU  - Vrieling, A.*
AU  - Zaineddin, A.K.*
AU  - Becker, S.*
AU  - Hüsing, A.*
AU  - Kaaks, R.*
AU  - Linseisen, J.
AU  - Flesch-Janys, D.*
AU  - Chang-Claude, J.*
C1  - 4864
C2  - 29453
CY  - Alexandria, VA
SP  - 3730-3738
TI  - Serum enterolactone and prognosis of postmenopausal breast cancer.
JO  - J. Clin. Oncol.
VL  - 29
IS  - 28
PB  - AMER SOC CLINICAL ONCOLOGY
PY  - 2011
SN  - 0732-183X
ER  - 

TY  - JOUR
AB  - Purpose CEBPA mutations are found as either biallelic (biCEBPA) or monoallelic (moCEBPA). We set out to explore whether the kind of CEBPA mutation is of prognostic relevance in cytogenetically normal (CN) acute myeloid leukemia (AML). Patients and Methods: Four hundred sixty-seven homogeneously treated patients with CN-AML were subdivided into moCEBPA, biCEBPA, and wild-type (wt) CEBPA patients. The subgroups were analyzed for clinical parameters and for additional mutations in the NPM1, FLT3, and MLL genes. Furthermore, we obtained gene expression profiles using oligonucleotide microarrays. Results: Only patients with biCEBPA had an improved median overall survival when compared with patients with wtCEBPA (not reached v 20.4 months, respectively; P = .018), whereas patients with moCEBPA (20.9 months) and wtCEBPA had a similar outcome (P = .506). Multivariable analysis confirmed biCEBPA, but not moCEBPA, mutations as an independent favorable prognostic factor. Interestingly, biCEBPA mutations, compared with wtCEBPA, were never associated with mutated NPM1 (0% v 43%, respectively; P < .001) and rarely associated with FLT3 internal tandem duplication (ITD; 5% v 23%, respectively; P = .059), whereas patients with moCEBPA had a similar frequency of mutated NPM1 and a significantly higher association with FLT3-ITD compared with patients with wtCEBPA (44% v 23%, respectively; P = .037). Furthermore, patients with biCEBPA showed a homogeneous gene expression profile that was characterized by downregulation of HOX genes, whereas patients with moCEBPA showed greater heterogeneity in their gene expression profiles. Conclusion: Biallelic disruption of the N and C terminus of CEBPA is required for the favorable clinical outcome of CEBPA-mutated patients and represents a distinct molecular subtype of CN-AML with a different frequency of associated gene mutations. These findings are of great significance for risk-adapted therapeutic strategies in AML.
AU  - Dufour, A.*
AU  - Schneider, F.*
AU  - Metzeler, K.H.*
AU  - Hoster, E.*
AU  - Schneider, S.*
AU  - Zellmeier, E.*
AU  - Benthaus, T.*
AU  - Sauerland, M.C.*
AU  - Berdel, W.E.*
AU  - Büchner, T.*
AU  - Wörmann, B.*
AU  - Braess, J.*
AU  - Hiddemann, W.
AU  - Bohlander, S.K.
AU  - Spiekermann, K.
C1  - 5140
C2  - 28184
CY  - Alexandria
SP  - 570-577
TI  - Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
JO  - J. Clin. Oncol.
VL  - 28
IS  - 4
PB  - Amer. Soc. Clinical Oncology
PY  - 2010
SN  - 0732-183X
ER  - 

TY  - JOUR
AU  - Gires, O.
AU  - Bauerle, P.A.*
C1  - 5850
C2  - 27689
SP  - E239-E240
TI  - EpCAM as a target in cancer therapy.
JO  - J. Clin. Oncol.
VL  - 28
IS  - 15
PB  - American Society of Clinical Oncology
PY  - 2010
SN  - 0732-183X
ER  - 

TY  - JOUR
AB  - Purpose: Recently, several novel molecular prognostic markers were identified in cytogenetically normal acute myeloid leukemia (CN-AML). In addition to the well-known influence of FLT3, NPM1, and CEBPA mutations, high transcript levels of the ERG, BAALC, and MN1 genes have been associated with inferior outcomes, but the relative importance of these risk markers remains to be defined. - Patients and Methods: We analyzed ERG, BAALC, and MN1 expression levels in a cohort of 210 patients with CN-AML who received intensive chemotherapy. Expression levels of ERG, BAALC, and MN1 were determined in bone marrow samples by using oligonucleotide microarrays. - Results: High transcript levels of ERG, BAALC, and MN1 were predictors for inferior overall survival (OS) and a lower rate of complete remissions (CRs). There were significant positive correlations between the expression levels of all three genes. ERG expression levels predicted OS in elderly patients (ie, age 60 years or older) with CN-AML (P = .006) as well as in younger patients (P = .013). In multivariate analyses, high ERG expression was independently associated with a lower CR rate (P = .013), shorter event-free survival (P = .008), and shorter OS (P = .005). Patients who had low ERG levels and absent FLT3 internal tandem duplication (ITD) had a 5-year OS of 44%, and patients who had high ERG expression and FLT3 ITD had a 5-year OS of only 5%. - Conclusion: We analyzed a comprehensive set of molecular risk factors in a large, homogeneous CN-AML patient cohort. In this study, high ERG expression levels emerged as a strong negative prognostic factor and provided prognostic information in addition to established molecular markers.
AU  - Metzeler, K.H.
AU  - Dufour, A.
AU  - Benthaus, T.
AU  - Hummel, M.
AU  - Sauerland, M.C.
AU  - Heinecke, A.
AU  - Berdel, W.E.
AU  - Büchner, T.
AU  - Wörmann, B.
AU  - Mansmann, U.
AU  - Braess, J.
AU  - Spiekermann, K.
AU  - Hiddemann, W.
AU  - Buske, C.
AU  - Bohlander, S.K.
C1  - 2415
C2  - 26954
CY  - Alexandria, USA
SP  - 5031-5038
TI  - ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: A comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
JO  - J. Clin. Oncol.
VL  - 27
IS  - 30
PB  - Amer Soc Clinical Oncology
PY  - 2009
SN  - 0732-183X
ER  - 

TY  - JOUR
AU  - van Glabbeke, M.*
AU  - Schlemmer, M.
C1  - 3698
C2  - 22939
SP  - 5795-5804
TI  - Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
JO  - J. Clin. Oncol.
VL  - 23
PY  - 2005
SN  - 0732-183X
ER  - 

TY  - JOUR
AB  - Purpose: To determine the efficacy of neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for local tumor control and overall survival (OS) in adult patients with retroperitoneal or visceral (RP/V) high-risk soft tissue sarcomas (HR-STS).Patients and Methods: From 1991 to 1997, 58 patients with HR-STS at RP/V sites were prospectively treated with four cycles of etoposide, ifosfamide, and doxorubicin combined with RHT followed by surgery, adjuvant chemotherapy, and radiation.
AU  - Wendtner, C.-M.*
AU  - Abdel-Rahman, S.*
AU  - Krych, M.*
AU  - Baumert, J.J.*
AU  - Lindner, L.H.*
AU  - Baur, A.*
AU  - Hiddemann, W.*
AU  - Issels, R.D.
C1  - 10090
C2  - 20276
SP  - 3156-3164
TI  - Response to Neoadjuvant Chemotherapy Combined with Regional Hyperthermia Predicts Long-Term Survival for Adult Patients with Retroperitoneal and Visceral High-Risk Soft Tissue Sarcomas. 
JO  - J. Clin. Oncol.
VL  - 20
PB  - American Society of Clinical Oncology
PY  - 2002
SN  - 0732-183X
ER  - 

TY  - JOUR
AU  - Issels, R.D.
AU  - Prenninger, S.W.
AU  - Nagele, A.
AU  - Boehm, E.
AU  - Sauer, H.
AU  - Jauch, K.-W.
AU  - Denecke, H.
AU  - Berger, H.
AU  - Peter, K.
AU  - Wilmanns, W.
C1  - 18335
C2  - 11526
TI  - Ifosfamide Plus Etoposide Combined with Regional Hyperthermia in Patients with Locally  Advanced Sarcomas: A Phase II Study.
JO  - J. Clin. Oncol.
PY  - 1990
SN  - 0732-183X
ER  -